| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 358.75 | 3.0% | 15.0% |
| Total Income | 360.92 | 5.0% | 14.6% |
| Expenditure | 344.27 | 6.3% | 22.4% |
| PBT | 16.66 | 70.3% | 50.7% |
| Net Profit | 13.39 | 67.9% | 47.0% |
| OPM | 8.63% | 8.15pp | 6.28pp |
| NPM | 3.71% | 7.27pp | 4.30pp |
| EPS | 2.80 | 68.0% | 46.9% |
Growth masked by an inventory echo; H2 should clear the air
Revenue grew 15% but profit fell 47%, courtesy of high-cost raw material inventory bought at the peak and expensed in Q2. The real story sits in the half-year numbers and October's recovery signal.
₹13.4 Cr
-47.0% YoY
₹56.2 Cr
+7.4% YoY
₹358.8 Cr
+15.0% YoY
The Q2 result lands with a puzzle: revenue climbs 15% year-on-year, a solid beat on industry growth, yet profit crashes 47%. The headline reads like a stumble. The call explains what happened — and why it wasn't.
The inventory echo
Indigo has been caught in a raw material price wave. In March–April 2026, crude spiked and paint feedstocks soared; the company bought inventory at the peak. That high-cost stock sat in the books and got expensed into Q2 COGS, depressing gross margin by 660 basis points. Management calls it 'the quirk of accountancy' — and it's real, not phantom. But it masks the operational picture. Q1 enjoyed the reverse phenomenon: low-cost inventory from before the spike got expensed into Q1 COGS, inflating EBITDA +42% year-on-year. Q2 hit the inverse. Together, H1 tells a steadier story: EBITDA margin 13.4%, down 170 bps, with PAT up 7.4% year-on-year. That's the organic run.
Margin breakdown: where the 660 bps fell
Management's claims, graded
Gross margin collapse is entirely inventory accounting, not operational failure.
Supported. Inventory accounts ~400 bps of 660 bps; mix is the remainder.
Q2 stand-alone revenue +14.1% YoY; industry grew 12–14%.
Supported. Consolidated +15% per delivered results; marginal outperformance.
October 2026 saw record monthly sales and highest Y-on-Y growth in 3–4 years.
Unverified. Stated post-Q2 close (Nov 2). Not in Q2 results; early signal of H2 recovery.
Jodhpur 90KL water-based plant fully operational by end-November 2026.
Supported on timeline. Trial started late Sept; target end-Nov. Minor fuzziness acknowledged.
No profitability shocks expected Q3 onwards; inventory is behind us.
Overstated. Contingent on crude $110–115 stability. Management: 'If crude goes through the roof, I can't predict.'
What changed on this call
The inventory burden is now explicit (prior call was vague). August already showed margin recovery as high-cost stock cleared; October's record sales claim—highest monthly Y-on-Y growth in 3–4 years—is a tangible early signal of H2 momentum. Guidance stance unchanged: no formal FY27 revenue target (prior call set the same tone), aggressive growth with accepted margin compression. Hemant Jalan continues dodging numeric targets ('I hesitate to give a number'), citing past over-commitment and current macro uncertainty. It's learning-and-caution, but also a guardrail on execution confidence.
Revenue +15% YoY, outpacing industry 12–14%
PAT -47% is inventory accounting shock, not operational failure
H1 EBITDA margin (13.4%, -170 bps) cleaner than Q2 in isolation
October record sales signal H2 momentum emerging
Jodhpur 90KL plant eliminates capex risk for 3 years
Dealer network (19,730) and reach (28 states, 6 plants) are structural
Price hikes (Nov 1 + Nov 21) risk volume elasticity in weak season
Geopolitical crude risk could repeat Q2-style margin shock
Management avoids numeric guidance; execution caution
Local competitors recovering ground (management's own words)
Risks, ranked by concern to a holder
Geopolitical crude spike (>$120)
HighUnhedgeable. Repeat of March–April surge loads high-cost inventory into Q3 books and repeats margin shock. Management flagged as 'beyond control.' Crude now $110–115 stable, but Middle East escalation is known risk.
Volume elasticity to stacked price hikes
MediumTwo price hikes in Nov (+10–12% total from March) test demand inelasticity at scale for first time. Paint 55%), so theory says demand inelastic. But 2–3 yrs price stability means behavior is unproven. Off-season (Nov–Dec) is wrong time to test.
Jodhpur plant execution delay
MediumTrial late Sept, target end-Nov full ops. Automation is complex; timeline fuzzy ('may happen 10–15 days earlier'). Even 2–3 week delay pushes Q3 contribution to Q4, and Q3 margin recovery leans on Jodhpur not adding cost.
Monsoon product mix overhang extends
MediumQ2 weakness in exterior paints (higher margin) due to monsoon. Management expects recovery in Q3 (festive season), but if monsoon extends or mix stays emulsion-heavy (lower margin), headwind persists into Q3.
Margin recovery contingent on macro, not just ops
MediumH2 guidance explicitly hedged on 'crude $110–115' and 'no geopolitical flare-up.' Conditional outlook, not commitment. Removes confidence if macro shifts.
Inventory accounting volatility repeats
Low-MediumIf raw material prices spike again, new high-cost inventory creates another swing in future quarters. Swing is real (COGS), but masks operational trends. Investors need to normalize for this.
How the street is positioned
The stock trades at ₹900.45, down sharply from its all-time high of ₹3,329.95 (drawdown of 73%). It sits below key moving averages: ₹992.95 (20-day), ₹1,069.14 (50-day), ₹999.32 (200-day). RSI is 31.7 (neutral). Volume is rising, signaling either capitulation or emerging interest. On ownership, FII have been net sellers: down 1.68 pp to 5.73% in Q1 FY27 (from 7.41% in Q4 FY26). DII have added: +2.25 pp to 25.25%. Promoters hold steady at 53.88%. On Aug 14, HDFC Mutual Fund bulk-bought 5,80,947 shares at ₹1,173.26 — a vote of confidence at prices well above today. The drawdown is steep; the valuation reset harsh. Q2 miss (-47% PAT) has driven FII exit; October recovery narrative hasn't yet anchored rebound. If H2 proves the recovery story, the valuation gap vs. historic multiples could trigger re-entry for institutions.
What to watch next
1 · Jodhpur plant: full operational status by end-Nov
Confirm 90KL plant running at intended capacity and margin-positive. Any delay or sub-capacity performance weakens H2 narrative. Track automation debugging daily for real-time progress.
2 · Margin recovery in Q3 (Oct–Dec festive quarter)
Look for EBITDA margin to expand materially from Q2 (8.6%) toward mid-teens. Driver: inventory clearing (done by Aug per mgmt), price-hike pass-through (Nov hikes), and mix recovery (festive season stronger in interior/premium). Flag October–November sales if disclosed.
3 · Crude oil forward: watch for spike toward $120+
If crude breaks $120, expect raw material re-acceleration and repeat high-cost inventory loading in Q3. $110–115 hold is green light; any jump is yellow flag for margin volatility.
Indigo Paints Q2 is a steady quarter hit by a temporary inventory timing shock. The company is not broken; it is in a margin compression cycle driven by raw material volatility and a deliberate strategy to pursue aggressive growth via price hikes and distribution. October's record sales claim, if sustained, validates H2 recovery. The real test is November and December: do price hikes hold volumes, does Jodhpur ramp as promised, and does crude stay stable? If all three check, the street's FII exit will look premature by Q3. If not, the case swings bear. The number to track from here is H2 EBITDA margin; hold mid-teens (15%+), and the thesis works. Miss it, and the debate reopens.
Inventory shock masks growth; recovery expected H2 if geopolitics hold
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Jodhpur timeline on track, inventory accounting explanation credible, margin recovery claims unproven. Avoids numeric guidance.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Revenue +15% YoY but PAT -47% due to inventory accounting shock now passing. Management credibly frames Q2 as temporary; October recovery narrative is early-stage. Jodhpur ramp real but risk of crude volatility and price-hike volume elasticity unproven.
₹358.8 Cr
Revenue · +15% YoY₹13.4 Cr
Reported PAT · −47% YoYCompressing
Margins · vs guidance: CorroboratedDid the claims hold up?
Gross margin collapsed 660 bps due to high-cost raw material inventory expensed in Q2
METQ2 gross margin 38.5% vs 45.1% PY = 660 bps decline. Inventory impact acknowledged; H1 margin 41.9% vs 45.6% = 370 bps (cleaner view).
Stand-alone revenue growth 14.1% YoY in Q2; industry grew 12-14%
METConsolidated Q2 revenue 358.7 Cr (+15% YoY per call, +15% per delivered). Marginal industry outperformance claimed.
October 2026 record sales, highest Y-on-Y monthly growth in 3-4 years
UnverifiedStated on call post-Q2 close (Nov 2). Not verified in Q2 results.
Jodhpur water-based plant will be fully operational by end of November 2026
METTrial production started late Sept; expects declaration of trial completion by end-Nov, definitely Dec. Concrete timeline but slightly fuzzy.
No future profitability shocks expected from Q3 onwards as inventory is behind us
OVERSTATEDContingent on raw material price stability (crude at $110-115). If geopolitical flare-up repeats, volatility returns. Acknowledged as beyond control.
Earnings quality
What changed since the last call
Inventory burden now visible; prior call vague
DowngradeQ1 FY27 benefited from low-cost inventory (EBITDA +42% YoY). Q2 reversed (-33% YoY) as high-cost stock expensed. No prior call predicted this swing.
October record sales claimed post-close
UpgradeStated on this call (Nov 2) that Oct had highest-ever monthly sales + Y-on-Y growth. Not in prior guidance but early signal of H2 recovery.
Guidance stance unchanged; no numeric targets
NeutralPrior call: no formal FY27 target, aggressive growth + margin compression. This call: same narrative, no number guidance ('I hesitate to give a number').
The Q&A
Analysts pressed hard on 3 themes: (1) gross margin breakdown (Kapadia got detailed inventory explanation), (2) sustainability of growth claims (Roy challenged 2x-3x industry language), (3) recovery credibility (Akhilesh B pushed on demand elasticity to price hikes). Management held firm on inventory-as-anomaly but dodged number guidance, citing geopolitical risk.
H2 margin recovery expectations — Abneesh Roy, Nuvama
AnsweredIf industry grows 12-15% in Q3 and we can do 23-25%, margins should improve substantially. Q4 historical precedent: EBITDA 23%, so 'not very pessimistic'.
Competitive dynamics and market share — Abneesh Roy, Nuvama
PartialLocal player data unpublished. Industry leader tends to gain disproportionately on price hikes. Competitors recovering ground now. 'Slightly weak base' of prior 2 years helps industry leader bounce.
Inventory and margin breakdown — Prakash Kapadia, Entrust
AnsweredProduct mix (premiums weak in Q2 monsoon) accounts ~2.5%, raw material inventory accounts ~4%. Q3 mix recovers, inventory clears by Aug, margins normalize. Not expecting repeat.
Water plant timeline and trial completion — Deepak Juneja, Individual
AnsweredTrial started late Sept. No permissions awaited (pollution, factory license, electric all in place). End-Nov target to declare trials over, definitely operational by Dec. Day-by-day debugging ongoing.
Raw material volatility and future shocks — Deepak Juneja, Individual
AnsweredHigh-cost inventory already expensed in Aug. Crude now $110-115 stable. If crude goes up again, yes, could repeat. Hedging options not available for paint raw materials. Manage via inventory.
Price hike absorption and volume elasticity — Aniruddha Joshi, ICICI
AnsweredPrice hikes dictated by industry leader. Timing/magnitude determined by leader, not followers. Inflation does not cover exact products. Demand historically inelastic to paint price (labor >55% of paint cost). No adverse volume impact seen so far.
Demand trends and market sentiment — Akhilesh B, Northstar
AnsweredDemand elasticity historically weak (paint is non-discretionary; bought once in 3-4 years). Prices flat for 2-3 years before this year's hikes. Demand recovery started post-Diwali 2025, accelerating. Not expecting margin headwind from demand.
Growth initiative details and competitive measures — Akhilesh B, Northstar
PartialMost initiatives confidential. Not just discounting (small part). Includes influencer engagement with painters/contractors, higher A&P spend (reflect in Q2 +1% of sales). Results to show in Q3-Q4.
Jodhpur plant capex and double-digit growth — Uchit Garg, Individual
AnsweredJodhpur new plant 90KL, modern with automation. More capacity than old plant, automation not present before. Even at 'best case' top-line growth, won't need major capex next 2-3 yrs. Capacity utilization peaks ~75% Oct, drops ~50-55% off-season, ~60% average. No constraint.
Raw material hedging strategy — Uchit Garg, Individual
AnsweredHedging options not available for paint raw materials (unlike copper/aluminum). Not commodities like that. Forward buying not possible. Manage via inventory and pricing discipline.
Guidance
No formal FY27 revenue target. Pursuing aggressive top-line growth 2x-3x industry growth.
LowHemant explicitly states 'I hesitate to give a number guidance.' Aspiration is 2x-3x but depends on industry growth (expects 12-15% in Q3). No FY27 end-target stated.
Gross margins to improve 'substantially' from Q3 onwards. EBITDA margins to 'normalize' H2.
MediumHigh-cost inventory cleared by Aug; pass-through complete by Sept per call. Price hikes implemented/planned in Nov. Conditions: crude stable, no new raw material shocks.
Jodhpur plant ₹275 Cr spend (major capex now complete). No material capex required for next 2-3 years post-Jodhpur.
HighNew plant 90KL capacity with automation eliminates need for major expansion. South India plant (commissioned 3 yrs ago) has excess capacity. Adequate for dual-digit growth.
Risks the call surfaced
Raw material volatility
HighCrude has spiked twice (March-April 2026 +doubling, July-Aug climb). No forward buying or hedging available for paint raw materials. Q2 inventory shock shows pass-through lag.
Volume elasticity to price hikes
MediumTwo price hikes announced in Nov (+10-12% total from March). Management claims demand inelastic (paint <50% of total painting cost), but 3.5 yrs of price stability prior means customer behavior untested at this scale.
Jodhpur plant execution risk
MediumJodhpur trial production started late Sept 2026. Full commercial operation target is end-Nov, but timeline is loose ('end of Nov is when we'll declare trials over; it may happen 10-15 days earlier'). Automation debugging ongoing daily.
Inventory accounting volatility
MediumQ1 benefited from expensing low-cost inventory purchased pre-March (EBITDA +42% YoY anomaly). Q2 reverse: high-cost inventory from March-April got expensed (-33% YoY). Management claims this is 'entirely because of the quirk of accountancy' but it masks operational volatility.
Margin recovery credibility
MediumManagement claims H2 EBITDA margin recovery to 'near normal' but avoids number guidance. Q4 typically strong (23% EBITDA margin historical). But Q3 recovery from -33% EBITDA growth is aggressive claim without quarterly target.
Management
Score 7/10. Clear on inventory mechanics and operational drivers (gross margin, product mix). Transparent about external volatility (geopolitical). Deliberately vague on number guidance ('I hesitate to give a number') to avoid repeat of prior missed targets. Defensive tone but honest. Jodhpur on schedule (trial Sept, full ops end-Nov). Gross margin recovery narrative credible (August recovery mentioned, Oct record sales). But Q2 miss on profitability (-47% PAT) shows execution gap vs market expectations.
1 · Nov-Dec 2026
Jodhpur plant full operational; gross margin stabilization
2 · Q3 FY27 (Oct-Dec)
Festive quarter strength + price hike absorption + inventory normalization
3 · H2 FY27
EBITDA margin recovery; outperformance vs industry if geopolitics stable
Jodhpur ramp real but risk of crude volatility and price-hike volume elasticity unproven.